Abiopharma

🔍 Saia John G. (Executive)

Company: Guardant Health, Inc. (GH)

Report Date: 2025-09-01

Detailed Transactions and Holdings:

• Acquired 264 shares of Common Stock (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,087.00 | transaction_form_type: 4
• Sold 139 shares of Common Stock at $67.42 per share (Direct)
  Date: 2025-09-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 44,948.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 264 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1

Footnotes:

• F1: Not applicable for Restricted Stock Units.
• F2: The restricted stock unit award was granted on November 2, 2021, and vested 25% of the shares subject to such award on September 1, 2022. The remaining 75% of the shares subject to such award vests in equal installments on each quarterly anniversary of September 1, 2022 during the three-year period thereafter.